跳至主要内容

博文

目前显示的是标签为“小分子PD-(L)1”的博文

贝达药业小分子PD-(L)1抑制剂专利公开

近日,贝达药业公开小分子PD-(L)1抑制剂专利——《IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF》,同样最早申请日可追溯到2019.1.31,此前本站也报道过东阳光小分子抑制剂专利情况,最早是2018.3申请。Recently, small molecules have been described to binding to PD-L1 in WO2015033299(Aurigene Discovery), WO2015033301(Aurigene Discovery), WO2015034820(Bristol-Myers Squibb), WO2018183171(Bristol-Myers Squibb), WO2018119224(Incyte), WO2018119266(Incyte, etc. Moreover, small molecule inhibitors that directly target PD-1 or PD-L1 are still not approved.Accordingly, there is still great demand for more potent, and more easily administered therapeutics against PD-1/PD-L1 protein/protein interactions. In this invention, applicant discovered potent small molecules that can have activity as inhibitors of the interaction of PD-L1 with PD-1, and thus may be useful for therapeutic administration to enhance immunity against cancer and/or infectious diseases. These small molecules are expected to be useful as pharmaceuticals with desirable stability, solubility, bi…